
Niraparib with AAP cut the risk of progression or death by 37% in HRR-altered mCSPC, according to data from the AMPLITUDE trial.

Niraparib with AAP cut the risk of progression or death by 37% in HRR-altered mCSPC, according to data from the AMPLITUDE trial.

The first-line regimen of disitamab vedotin, toripalimab, and trastuzumab revealed superior efficacy and response rates vs disitamab vedotin, toripalimab, and chemotherapy in HER2-expressing locally advanced or metastatic G/GEJ cancer.

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a potential new therapy in the space.

Radium-223 in mCRPC showed long-term favorable safety, low second primary malignancies/fracture rates, and consistent overall survival.

EBC-129 demonstrates early activity and manageable safety in patients with heavily pretreated pancreatic cancer, supporting further development.

Patritumab deruxtecan did not improve overall survival compared to chemotherapy in EGFR-mutated NSCLC, despite showing PFS and ORR benefits previously.

Nivolumab plus ipilimumab showed activity in mCRPC, and while adding SBRT was safe, it did not boost efficacy in the CheckPRO trial.

Most CRS, ICANS, and neuro events after liso-cel were mild and occurred within 15 days post-infusion, according to different clinical trial and real-world settings.

The ANZUP 1301 trial showed that BCG and mitomycin showed similar DFS to BCG alone in NMIBC, but with 40% fewer BCG doses and similar safety.

Extended follow-up of MonumenTAL-1 shows talquetamab-tgvs yields durable ORRs and promising survival outcomes in relapsed/refractory multiple myeloma, with a tolerable safety profile.

Shlomo Koyfman, MD, discusses the MK-3475-630/KEYNOTE-630 trial, which focused on patients with high-risk cutaneous squamous cell cancer.

Ribociclib combined with aromatase inhibitors shows significant survival benefits for early-stage hormone receptor-positive breast cancer, enhancing treatment outcomes across patient demographics.

The SACHI trial showed savolitinib + osimertinib significantly improved PFS (8.2 vs 4.5 months) vs chemotherapy in EGFR-mutated, MET-amplified advanced NSCLC after EGFR TKI progression.

EMBER-3 trial results show imlunestrant, alone or with abemaciclib, improves patient-reported outcomes for ER+/HER2- advanced breast cancer after endocrine therapy.

The NeoSTAR trial showed neoadjuvant sacituzumab govitecan and pembrolizumab achieved a 32% pCR rate in early-stage TNBC, with promising efficacy and a tolerable safety profile.

Sevabertinib demonstrated high and durable objective response rates in pretreated and treatment-naive HER2-mutant NSCLC, with a manageable safety profile.

A randomized phase 2 study of a GSK-3ß inhibitor plus gemcitabine/nab-paclitaxel showed survival benefit in patients with untreated metastatic pancreatic ductal adenocarcinoma.

An updated 4-year analysis indicates nivolumab/relatlimab offers comparable PFS and OS to nivolumab/ipilimumab in advanced melanoma, with lower toxicity.

Zanubrutinib shows durable efficacy in CLL/SLL with 17p deletions, according to 5-year SEQUOIA trial data.

Adagrasib plus pembrolizumab improved efficacy in KRAS G12C-mutant NSCLC, according to data from the KRYSTAL-7 trial.

Fruquintinib plus camrelizumab, paclitaxel liposome, and nedaplatin showed a 68.4% ORR and acceptable safety in advanced ESCC.

At ASCO 2025, Suneel Kamath, MD, presented an analysis of federal cancer research funding disparities and their ripple effects on care delivery and outcomes.

Camizestrant plus CDK4/6 inhibition improved progression-free survival when given to patients with ESR1-mutant ER+/HER2– breast cancer in the SERENA-6 trial.

Neoadjuvant PAXG led to a significant improvement in event-free survival vs mFOLFIRINOX in resectable or borderline resectable pancreatic ductal adenocarcinoma.

Adjuvant nivolumab offered sustained survival benefits in resected esophageal/GEJ cancer post chemoradiation, with PD-L1 emerging as a potential biomarker.

Nivolumab with cisplatin and radiotherapy improved disease-free survival in high-risk locally advanced squamous cell carcinoma of the head and neck in the NIVOPOSTOP trial.

Durvalumab plus FLOT improved event-free survival vs placebo in resectable gastric/GEJ cancer.

A 3-year structured exercise program significantly improved DFS and OS in stage II/III CRC, reducing recurrence by 28% and death risk by 37%.

Less inflammatory diets were linked to improved overall survival in stage III colon cancer, and physical activity showed synergistic benefits.
